PURPOSE: Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side effects, which necessitates evaluation of health-related quality of life (HRQOL). Our trial examined the HRQOL effects of adjuvant pegylated IFN-alpha-2b (PEG-IFN-alpha-2b) versus observation in patients with stage III melanoma. METHODS: A total of 1,256 patients with stage III melanoma were randomly assigned after full lymphadenectomy to receive either observation (n = 629) or PEG-IFN-alpha-2b (n = 627): induction 6 micrograms/kg/wk [DOSAGE ERROR CORRECTED] for 8 weeks then maintenance 3 micrograms/kg/wk [DOSAGE ERROR CORRECTED] for an intended total duration of 5 years. The European Organisation for Research and Treatment of Cancer Quality of...
Item does not contain fulltextCurrently the data from 12 randomised phase III trials investigating t...
Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 tri...
textabstractThe lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuv...
PURPOSE: Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side ef...
Purpose Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side eff...
BACKGROUND: Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duratio...
Background Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration...
Purpose: To evaluate the quality-of-life effects of ad-juvant igh-dose interferon alfa-2b (IFNa2b) t...
Purpose: Adjuvant pegylated interferon alfa-2b (PEG-IFN-α-2b) was approved for treatment of resected...
Contains fulltext : 49192.pdf (publisher's version ) (Closed access)BACKGROUND: In...
Background: Subgroup analyses of two large EORTC adjuvant interferon-alpha2b (IFNα-2b) vs observatio...
Item does not contain fulltextAdjuvant interferon has modest activity in melanoma patients at high r...
PURPOSE: Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared ...
Abstract Background High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, ...
A definitive conclusion regarding the value of low-dose extended duration adjuvant interferon-alpha ...
Item does not contain fulltextCurrently the data from 12 randomised phase III trials investigating t...
Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 tri...
textabstractThe lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuv...
PURPOSE: Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side ef...
Purpose Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side eff...
BACKGROUND: Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duratio...
Background Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration...
Purpose: To evaluate the quality-of-life effects of ad-juvant igh-dose interferon alfa-2b (IFNa2b) t...
Purpose: Adjuvant pegylated interferon alfa-2b (PEG-IFN-α-2b) was approved for treatment of resected...
Contains fulltext : 49192.pdf (publisher's version ) (Closed access)BACKGROUND: In...
Background: Subgroup analyses of two large EORTC adjuvant interferon-alpha2b (IFNα-2b) vs observatio...
Item does not contain fulltextAdjuvant interferon has modest activity in melanoma patients at high r...
PURPOSE: Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared ...
Abstract Background High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, ...
A definitive conclusion regarding the value of low-dose extended duration adjuvant interferon-alpha ...
Item does not contain fulltextCurrently the data from 12 randomised phase III trials investigating t...
Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 tri...
textabstractThe lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuv...